TLDR: A run of 2025 clearances moved consumer and home devices from wellness gadgets into regulated diagnostics. Samsung’s Galaxy Watch sleep-apnea feature earned United States Food and Drug Administration (FDA) authorization and reached 70 markets, ResMed launched a coin-sized finger-worn home apnea test, and Dexcom cleared a 15-day glucose sensor. Diagnosis is moving from the lab to the wrist and the home, and regulatory clearance has become the line that separates a gadget from a medical device.
Sleep apnea moves to the wrist
Samsung turned a mainstream smartwatch into a screening tool. Its obstructive sleep apnea feature holds FDA De Novo authorization, and the company announced a research collaboration with Stanford Medicine to advance detection and move toward ongoing management. The feature detects signs of moderate to severe apnea over a two-night window and now reaches 70 markets worldwide.
The significance lies in the distribution. Sleep apnea remains widely undiagnosed, and a clinically authorized feature on a device millions already wear turns a consumer product into a front door for care. Screening reaches people who would otherwise wait years for a referral.
The home test shrinks to a fingertip
ResMed addressed the diagnostic step itself. The company launched NightOwl across the United States, an FDA-cleared home sleep apnea test about the size of a coin that a patient wears on a fingertip for up to ten nights. The sensor reads movement, pulse rate, blood oxygen, and peripheral arterial tone, then sends data to a cloud platform for physician review.
A validation study showed close agreement with expert-scored lab testing. By moving an accurate diagnostic into the home at low cost, ResMed compresses a process that once required a sleep-lab visit, which widens access and shortens the path to treatment.
The sensor stretches to fifteen days
Dexcom pushed continuous monitoring further. The company earned FDA clearance for its G7 15 Day continuous glucose monitoring system, the longest-lasting wearable sensor of its kind, with an accuracy figure (a mean absolute relative difference of 8.0%) that sets a high bar. The longer wear time lowers cost per day and reduces the friction of frequent sensor changes.
Continuous glucose data has already expanded beyond diabetes into metabolic health and wellness. A longer, more accurate sensor strengthens that expansion and deepens the stream of real-world data that informs care.
What it means for medtech innovators
The throughline is a shift in where diagnosis happens and what makes it credible. The wrist, the fingertip, and the home now host tools that regulators have cleared, and that clearance is the differentiator. A wellness claim invites scepticism, while an FDA authorization earns clinician trust, reimbursement conversations, and a durable market position.
That distinction defines the opportunity for corporates and innovators in medical devices. The winners pair consumer-grade design and scale with clinical-grade evidence and regulatory clearance, then build the data and adherence layer on top. The 9 Months Later programme works with exactly this kind of organisation, helping medtech leaders move an idea through validation and regulation into routine clinical use. The lab is coming to the patient, and the device that arrives with proof will own the moment.
References
- Samsung announces collaboration with Stanford Medicine to advance sleep apnea detection: https://news.samsung.com/global/samsung-announces-collaboration-with-stanford-medicine-to-advance-sleep-apnea-detection-and-beyond
- ResMed debuts wearable, at-home sleep apnea test (NightOwl): https://www.fiercebiotech.com/medtech/resmed-debuts-wearable-home-sleep-apnea-test
- Dexcom G7 15 Day receives FDA clearance, the longest-lasting wearable CGM system: https://www.businesswire.com/news/home/20250410304660/en/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System
